Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition

@inproceedings{Tel2016PreclinicalEO,
  title={Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition},
  author={Jurjen Tel and Rutger H. T. Koornstra and Nienke de Haas and Vincent van Deutekom and Harm Westdorp and Steve Boudewijns and Nielka P H van Erp and Stefania Di Blasio and Winald R. Gerritsen and Carl G. Figdor and I Jolanda M de Vries and Stanleyson V. Hato},
  booktitle={Journal of Translational Medicine},
  year={2016}
}
Melanoma is the most lethal type of skin cancer and its incidence is progressively increasing. The introductions of immunotherapy and targeted therapies have tremendously improved the treatment of melanoma. Selective inhibition of BRAF by vemurafenib results in objective clinical responses in around 50 % of patients suffering from BRAFV600 mutated melanoma. However, drug resistance often results in hampering long-term tumor control. Alternatively, immunotherapy by vaccination with natural… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Selective BRAFV600E Page 11 of 11

  • A Boni, AP Cogdill, +7 authors DE Fisher
  • Tel et al. J Transl Med
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…